Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Debiopharm enters license agreement for European marketing of Salvacyl/Moapar

May 19, 2008

PDC and Theratechnologies sign license agreement for PDC-31

May 19, 2008

Chugai and Taisho sign agreement to codevelop and comarket eldecalcitol for osteoporosis

May 16, 2008

Ardana reports preliminary results from phase III study of testosterone cream in hypogonadal men

May 16, 2008

Novel sEH inhibitor shows benefit in mouse model of obesity

May 15, 2008

Ambrilia presents positive final phase III results for Octreotide C2L

May 15, 2008

Takeda and Affymax report results from three phase II trials of Hematide

May 15, 2008

Piramal Life Sciences initiates phase I trials with P-1736 for type 2 diabetes

May 15, 2008

Cholesterol lowering with AVE-5530 described in animals

May 15, 2008

Proellex shows no adverse cardiac effects in a pilot trial

May 14, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...